

REQUEST FOR ACCESS TO AN ABANDONED APPLICATION UNDER 37 CFR 1.14

Bring completed form to:
File Information Unit
Crystal Plaza Three, Room 1D01
2021 South Clark Place
Arlington, VA
Telephone: (703) 308-2733

RECEIVED

MAR 19 2004

File Information Unit

In re Application of

Application Number

08/883 803

File

No. 9

904

Paper No.

#9

I hereby request access under 37 CFR 1.14(a)(1)(iv) to the application file record of the above-identified ABANDONED application, which is identified in, or to which a benefit is claimed, in the following document (as shown in the attachment):

United States Patent Application Publication No. _____, page, _____ line _____.

United States Patent Number 6037 368, column 1, line, 1 or _____.

WIPO Pub. No. _____, page _____, line _____.

Related Information about Access to Pending Applications (37 CFR 1.14):

Direct access to pending applications is not available to the public but copies may be available and may be purchased from the Office of Public Records upon payment of the appropriate fee (37 CFR 1.19(b)), as follows:
For published applications that are still pending, a member of the public may obtain a copy of:

- the file contents;
- the pending application as originally filed; or
- any document in the file of the pending application.

For unpublished applications that are still pending:

- (1) If the benefit of the pending application is claimed under 35 U.S.C. 119(e), 120, 121, or 365 in another application that has: (a) issued as a U.S. patent, or (b) published as a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of:
 - the file contents;
 - the pending application as originally filed; or
 - any document in the file of the pending application.
- (2) If the application is incorporated by reference or otherwise identified in a U.S. patent, a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of:
 - the pending application as originally filed.

Signature

Ricardo Alvarado

Typed or printed name

703 268 3244

Registration Number, if applicable

Telephone Number

Date

3-19-04

FOR PTO USE ONLY

Approved by

RECEIVED

Unit:

MAR 19 2004

File Information Unit



US006037368A

United States Patent [19]**Podos et al.**[11] **Patent Number:** **6,037,368**[45] **Date of Patent:** **Mar. 14, 2000**[54] **8-ISO- PROSTAGLANDINS FOR GLAUCOMA THERAPY**[75] Inventors: **Steven M. Podos**, Tenafly, N.J.;
Thomas W. Mittag, Pleasantville, N.Y.;
Bernard Becker, University City, Mo.[73] Assignee: **Mount Sinai School of Medicine**, New York, N.Y.[21] Appl. No.: **09/073,552**[22] Filed: **May 6, 1998****Related U.S. Application Data**

[63] Continuation of application No. 08/853,803, May 9, 1997, abandoned.

[51] Int. Cl.⁷ **A61K 31/215**; A61K 31/19[52] U.S. Cl. **514/530**; 514/573; 514/913[58] Field of Search 514/530, 573,
514/913[56] **References Cited****U.S. PATENT DOCUMENTS**4,132,847 1/1979 Kuhla et al. .
4,599,353 7/1986 Bito .
5,151,444 9/1992 Ueno et al. .
5,173,507 12/1992 DeSantis et al. .5,208,256 5/1993 Ueno .
5,262,437 11/1993 Chan .
5,462,968 10/1995 Woodward .
5,476,872 12/1995 Garst et al. .
5,565,492 10/1996 DeSantis et al. .
5,578,618 11/1996 Stjernschantz .
5,631,287 5/1997 Schneider 514/530**FOREIGN PATENT DOCUMENTS**

9411002 5/1994 WIPO .

OTHER PUBLICATIONS

Podos et al., Mar. 15, 1998, Invest. Ophthalmol. Visual Sci. 39(4):S258, abstract 1178-B57 (title on the Internet several months earlier, believed to be in 1998).

Wang et al., Mar. 15, 1997, Invest. Ophthalmol. Visual Sci. 38(4):S815, abstract 3795-B396.

Primary Examiner—Zohreh Fay*Attorney, Agent, or Firm*—Bakerbotts LLP[57] **ABSTRACT**

The present invention relates to the use of 8-iso prostaglandins and their derivatives for decreasing intraocular pressure, for example in the treatment of glaucoma. It is based, at least in part, on the discovery that 8-iso prostaglandin E₂ effectively decreased intraocular pressure by a trabecular meshwork outflow mechanism.

21 Claims, No Drawings